Relationship between caffeine-induced ocular hypertension and ultrastructure changes of non-pigmented ciliary epithelial cells in rats.
The purpose of this study was to morphologically assess a possible mechanism for caffeine-induced ocular hypertension. Taking into consideration the relationship between the secretion of aqueous humor and the ultrastructure of the ciliary body, the time course of the morphological features in the ciliary epithelium when caffeine was administered intravenously to male Wistar rats was investigated by electron-microscopy. These morphological findings were also compared with the changes in the intraocular pressure (IOP). A significant increase in IOP was noted 15 min and 1 hr after a single dosing of caffeine alone. This change disappeared in all animals within 2 hr after dosing. The IOP in the animals receiving caffeine and the beta-blocker befunolol, which lowers the IOP by inhibiting aqueous humor secretion, decreased significantly from 15 min after dosing, and this change persisted 2 hr after dosing. In electron-microscopy 15 min and/or 1 hr after dosing with caffeine, a slight dilatation in the lateral intercellular spaces near the basement membrane of the non-pigmented ciliary epithelium was observed and the interdigitations between the non-pigmented epithelial cells were intact. Reversal of these changes was observed 2 hr after dosing. On the other hand, the lateral intercellular spaces between the non-pigmented epithelial cells were markedly dilated and the interdigitations were disorganized following dosing with caffeine alone and in combination with befunolol. These results described here indicate that the intravenous administration of caffeine causes ocular hypertension and also changes in the non-pigmented ciliary epithelium, suggesting an enhancement of aqueous humor transportation. This paradigm in the rat is considered to be useful to further assess caffeine-induced ocular hypertension and for use as an animal model in glaucoma research associated with an aqueous humor secretion.
Kurata
K
K
Drug Safety Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, Japan.
Maeda
M
M
Nishida
E
E
Tsukuda
R
R
Suzuki
T
T
Ando
T
T
Tokuriki
M
M
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001082:Aqueous Humor / Q000378:metabolism; D002110:Caffeine / Q000633:toxicity*; D002924:Ciliary Body / Q000187:drug effects* / Q000648:ultrastructure*; D004847:Epithelial Cells / Q000187:drug effects / Q000648:ultrastructure; D007275:Injections, Intravenous; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D009798:Ocular Hypertension / Q000139:chemically induced*; D011412:Propanolamines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D002110:Caffeine; C006034:befunolol